Literature DB >> 19545735

Efficacy of total lymphoid irradiation in azithromycin nonresponsive chronic allograft rejection after lung transplantation.

G M Verleden1, Y Lievens, L J Dupont, D E Van Raemdonck, S I De Vleeschauwer, R Vos, B M Vanaudenaerde.   

Abstract

Bronchiolitis obliterans syndrome (BOS) remains a major problem after lung transplantation. Azithromycin seems to be beneficial in some patients with established BOS. We investigated the efficacy of total lymphoid irradiation (TLI) in 6 BOS patients with a continuous decline in FEV(1), despite treatment with azithromycin for a mean of 12 +/- 13 (range, 1-35) months. A historical control group consisted of 5 patients with declining FEV(1), also nonresponders to azithromycin and those not treated with TLI. All 6 TLI patients received the total dose of 8 Gy in 10 sessions. There was a significant change in the decline of the FEV(1) after TLI treatment (from 221 +/- 107 to 94 +/- 79 mL/mo; P = .041). Three patients died, due to BOS progression, overwhelming pneumonia, and sudden cardiac arrest, respectively, 3.5, 11, and 26 months after TLI; two patients underwent retransplantation at 6 and 19 months after TLI, respectively. The sixth patient remains stable in BOS stage 3 after a follow-up period of 24 months. In the control group, there was no significant change in FEV(1) decline (209 +/- 97 mL/mo before versus 193 +/- 81 mL/mo after starting azithromycin; P = not significant). Two patients remain stable in BOS stage 3, 1 died of BOS progression, and the 5th patient is scheduled for retransplantation. We conclude that patients who do not or no longer respond to azithromycin may benefit from TLI, as suggested by a decreased rate in decline of the FEV(1).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19545735     DOI: 10.1016/j.transproceed.2009.03.070

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  11 in total

Review 1.  Immunosuppression and allograft rejection following lung transplantation: evidence to date.

Authors:  Gregory I Snell; Glen P Westall; Miranda A Paraskeva
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 2.  Diagnosis, Pathophysiology and Experimental Models of Chronic Lung Allograft Rejection.

Authors:  Jason M Gauthier; Daniel Ruiz-Pérez; Wenjun Li; Ramsey R Hachem; Varun Puri; Andrew E Gelman; Daniel Kreisel
Journal:  Transplantation       Date:  2018-09       Impact factor: 4.939

Review 3.  The Evolution of Lung Transplant Immunosuppression.

Authors:  Steven Ivulich; Glen Westall; Michael Dooley; Gregory Snell
Journal:  Drugs       Date:  2018-07       Impact factor: 9.546

Review 4.  Immunosuppression in Lung Transplantation.

Authors:  Joelle Nelson; Elisabeth Kincaide; Jamie Schulte; Reed Hall; Deborah Jo Levine
Journal:  Handb Exp Pharmacol       Date:  2022

Review 5.  Chronic lung allograft dysfunction.

Authors:  Anupam Kumar; Puneet Singh Garcha
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2021-11-16

6.  Managing bronchiolitis obliterans syndrome (BOS) and chronic lung allograft dysfunction (CLAD) in children: what does the future hold?

Authors:  Gregory I Snell; Miranda Paraskeva; Glen P Westall
Journal:  Paediatr Drugs       Date:  2013-08       Impact factor: 3.022

7.  Montelukast for bronchiolitis obliterans syndrome after lung transplantation: A randomized controlled trial.

Authors:  David Ruttens; Stijn E Verleden; Heleen Demeyer; Dirk E Van Raemdonck; Jonas Yserbyt; Lieven J Dupont; Bart M Vanaudenaerde; Robin Vos; Geert M Verleden
Journal:  PLoS One       Date:  2018-04-06       Impact factor: 3.240

Review 8.  Management of chronic rejection after lung transplantation.

Authors:  Bahaa Bedair; Ramsey R Hachem
Journal:  J Thorac Dis       Date:  2021-11       Impact factor: 2.895

Review 9.  An update on current treatment strategies for managing bronchiolitis obliterans syndrome after lung transplantation.

Authors:  Ashwini Arjuna; Michael T Olson; Rajat Walia; Ross M Bremner; Michael A Smith; Thalachallour Mohanakumar
Journal:  Expert Rev Respir Med       Date:  2020-10-25       Impact factor: 3.772

Review 10.  Beyond cancer treatment - a review of total lymphoid irradiation for heart and lung transplant recipients.

Authors:  Clare McKay; Kellie A Knight; Caroline Wright
Journal:  J Med Radiat Sci       Date:  2014-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.